OPKO Health is a multinational biopharmaceutical and diagnostics company based in key sectors of healthcare, basing its activity on the discovery, development, and commercialization of novel products.

It is currently developing a wide range of solutions for the diagnosis, treatment and prevention of various pathologies, including “Point of Care” technologies, molecular diagnostic tests, drugs and vaccines.

OPKO Health has subsidiaries companies in the USA, Chile, Spain (OPKO Europe), Mexico, Portugal, Uruguay, Brazil, Ecuador and France. The division of API and chemical development is in Israel, in which the base molecules and compounds for our diagnostic and therapeutic products are developed. The US has a CLIA certified laboratory (OPKO Lab), which develops its core business in the field of urology. Through our therapeutic divisions, OPKO Renal and OPKO Biologics, it focuses on developing new therapies in the fields of nephrology and endocrinology.

OPKO is actively exploring new opportunities to acquire pharmaceutical products and new technologies in areas of our special interest. In short, we are confident that OPKO will provide over the next few years, a significant contribution to improving the health of patients of different pathologies.